StockNews.AI
VXRT
StockNews.AI
251 days

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

1. Vaxart executives will present at World Vaccine Congress on April 23, 2025. 2. Presentations include oral norovirus vaccine and blocking transmission strategies. 3. Vaxart develops oral vaccines that don't require refrigeration, enhancing distribution. 4. The company is progressing in therapeutic vaccines for HPV and other pathogens. 5. Vaxart holds extensive patents on its unique oral vaccination technology.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive visibility at a prominent conference could attract investor interest and partnerships, akin to past biotech advancements that spurred stock appreciation.

How important is it?

The article highlights key upcoming presentations that may boost investor sentiment, crucial for a clinical-stage biotech company.

Why Short Term?

The immediate attention from the upcoming conference may lead to quick investor reactions and potential short-term price movements, frequently seen in biotech events.

Related Companies

NVAXMRNAPFEJNJ
April 16, 2025 08:00 ET  | Source: Vaxart, Inc. SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. James F. CummingsDate: Wednesday, April 23, 2025 Time: 1:10 p.m. ETRoom: 207A Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infectionSpeaker: Dr. Sean TuckerDate: Wednesday, April 23, 2024 Time: 3:10 p.m. ETRoom: 207A About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. ContactVaxart Media and Investor Relations:   Matt Steinberg      FINN PartnersIR@vaxart.com(646) 871-8481 This press release was published by a CLEAR® Verified individual.

Related News